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Abstract
Background: Human metapneumovirus (HMPV) is established as one of the causative agents of respiratory tract
infections. To date, there are limited reports that describe the effect of HMPV genotypes and/or viral load on
disease pathogenesis in adults. This study aims to determine the role of HMPV genetic diversity and
nasopharyngeal viral load on symptom severity in outpatient adults with acute respiratory tract infections.
Methods: Severity of common cold symptoms of patients from a teaching hospital was assessed by a four-
category scale and summed to obtain the total symptom severity score (TSSS). Association between the fusion and
glycoprotein genes diversity, viral load (quantified using an improved RT-qPCR assay), and symptom severity were
analyzed using bivariate and linear regression analyses.
Results: Among 81/3706 HMPV-positive patients, there were no significant differences in terms of demographics,
number of days elapsed between symptom onset and clinic visit, respiratory symptoms manifestation and severity
between different HMPV genotypes/sub-lineages. Surprisingly, elderly patients (≥65 years old) had lower severity of
symptoms (indicated by TSSS) than young and middle age adults (p = 0.008). Nasopharyngeal viral load did not
correlate with nor predict symptom severity of HMPV infection. Interestingly, at 3–5 days after symptom onset,
genotype A-infected patients had higher viral load compared to genotype B (4.4 vs. 3.3 log10 RNA copies/μl)
(p = 0.003).
Conclusions: Overall, HMPV genetic diversity and viral load did not impact symptom severity in adults with acute
respiratory tract infections. Differences in viral load dynamics over time between genotypes may have important
implications on viral transmission.
Keywords: Human metapneumovirus (HMPV), Genetic diversity, Viral load, Symptom severity, Acute respiratory tract
infection
Background
Human metapneumovirus (HMPV) is a negative-stranded
RNA virus classified in the Pneumoviridae family [1].
HMPV infections are commonly associated with mild
respiratory symptoms, but severe cough, bronchiolitis and
pneumonia have also been reported, sometimes accom-
panied by high fever, myalgia and vomiting [2]. Several
risk factors associated with more severe disease due to
HMPV infection in adults have been identified, which in-
clude patients with pulmonary disease or congestive heart
disease, healthy elderly patients with age over 65 years old,
long term stay in hospital care facilities and immunocom-
promised patients [3].
Previous reports had attempted to associate the genetic
diversity of HMPV, which are classified as genotypes A
and B (with further classification into sub-lineages - A1,
A2a, A2b, B1 and B2) [4] with disease severity [5–7]. For
instances, it was found that HMPV genotype A infection
in children caused more severe illnesses (e.g. higher risk of
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pneumonia and oxygen saturation < 90%, need for
hospitalization, and longer stay of intensive care unit)
compared with genotype B infection [7]. In contrast, some
studies reported that genotype B infection was one of the
risk factor for severe disease [5] with more pathological
signs on chest X-ray compared with genotype A infection
[6]. Furthermore, some associations remain debatable as
several studies found no direct correlation between
HMPV genotypes and severity of illness [8–10]. On the
other hand, apart from viral genetic diversity, HMPV viral
load was recognized as a risk factor associated with more
severe disease outcome leading to hospitalization [11, 12].
Although HMPV genetic diversity continues to be de-
scribed and linked with disease severity in hospitalized
children [6], pediatrics [13], elderly adults [10] and
immunocompromised patients [3], reports that address
this association have been limited in the adult outpatient
settings. A recent study which showed that HMPV can
also cause respiratory outbreaks in adults [14] highlights
the fact that adults may play a role in the transmission
and evolutionary dynamics of the virus, and more severe
disease could occur in adults during an outbreak.
Hence, in this study, we sought to investigate the pos-
sible linkage of genetic diversity on symptom severity in
adult outpatients with HMPV infection presenting acute
upper respiratory tract infections (URTI) [15]. Using an
improved molecular assay for viral load quantification,
we also assessed the correlation of HMPV viral load in
nasopharyngeal specimens on symptom severity.
Methods
Sample collection, symptom severity assessment, and
HMPV genotyping
A total of 3706 consenting adult outpatients who pre-
sented with symptoms of acute URTI for not more than
two weeks were recruited at the Primary Care Clinic of
University of Malaya Medical Centre (UMMC) in Kuala
Lumpur, Malaysia between February 2012 and May
2014. During enrollment, participants were interviewed
to determine their demographics (age, gender and
ethnicity), estimated number of days elapsed between
symptom onset and clinic visit or enrollment date, and
the presence and severity of common cold symptoms
[16, 17]. The common cold symptoms assessed were
sneezing, nasal discharge, nasal congestion, cough, sore
throat, hoarseness of voice, headache and muscle ache.
The severity of each symptom was then rated by a stan-
dardized four-category ordinal scale previously reported
[16–19]: none (0), mild (1), moderate (2) and severe (3).
The symptom ratings were summed to create a total
symptom severity score (TSSS) for each participant with
a maximum points of 24 from eight symptoms [20], in
which greater symptom severity was indicated by a
higher score.
Nasopharyngeal swabs were collected from the pa-
tients and transferred to the laboratory in universal
transport media (Copan Diagnostics, California, USA).
Total nucleic acid purification was performed using the
NucliSENS easyMAG automated nucleic acid extraction
system (bioMérieux, Marcy I’Etoile, France) according to
manufacturer’s protocol [21]. The xTAG Respiratory
Virus Panel (RVP) FAST multiplex RT-PCR assay
(Luminex Molecular, Toronto, Canada) and Luminex’s
proprietary Universal Tag sorting system on Luminex
200 IS platform (Luminex Corp., Austin, Texas, USA)
were used to detect HMPV in the samples [22]. The
genotype of HMPV-positive samples was first deter-
mined by performing amplification and sequencing of
the fusion (F) and attachment (G) genes as previously
described [15]. This was followed by phylogenetic tree
reconstruction using the maximum-likelihood (ML)
method which was heuristically inferred using subtree
pruning and regrafting and nearest neighbor interchange
algorithms with a general time-reversible (GTR) nucleo-
tide substitution model, a proportion of invariant sites
(+I) and four categories of gamma rate heterogeneity
(+Γ4), which were implemented in PAUP version 4.0
[23]. Kimura’s two-parameter model with a reliability of
branching order analyzed by bootstrap replicates of 1000
was used.
HMPV viral load quantification
For improved quantification of HMPV RNA in the naso-
pharyngeal specimens, a comprehensive and updated list
of reference genomes was used to design a quantitative
one-step reverse transcriptase-quantitative polymerase
chain reaction (RT-qPCR) assay. Newly designed primer
pair and a fluorescent probe targeting the highly con-
served M2 gene [24] of HMPV were developed based on
a set of global HMPV complete genomes representing
all genotypes A1, A2a, A2b, B1 and B2 (n = 135) avail-
able in GenBank (retrieved on 31 January 2016). The se-
quences were codon-aligned using the web-based
multiple sequence alignment program MAFFT [25] to
look for conserved regions of the complete genome.
Highly conserved forward primer, reverse primer and
the probe with a coverage of 99.3, 100, and 99.3%, re-
spectively, based on the alignment of the global refer-
ence sequence (Additional file 1), were designed using
the Primer Express Software v2.0 (Applied Biosys-
tems, California, USA). With reference to the nucleo-
tide numbering of NC_004148 (HMPV reference
strain), the forward primer (designated as 4730f ), re-
verse primer (4919r) and probe (4796fp) spanned the
genetic regions corresponding to nucleotide positions
4730–4754, 4919–4893 and 4796–4814 nt, respect-
ively. The probe was labeled with the 6-fluorescein
amidite (FAM) at the 5′ end, and the non-fluorescent
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quencher (NFQ) and minor groove binder (MGB) at the
3′-end. A synthetic single-stranded RNA oligonucleotide
with a randomly generated sequence was designed and
used as internal control (IC) to check for potential PCR
inhibition. The unique IC sequence (5′-ACATCGTAA
GGCTCCATGCAAATATGAAGATAGAATGCTTAGGA
CCATCAGCGAAACTCTACAATAATATCAGGCGCAG
GCAGAGAAGTA-3′) showed < 10% similarity with any
published sequence in the GenBank (data not shown). The
IC was flanked by sequences similar to the primer binding
site of the newly designed HMPV primer set, with a unique
non-HMPV probe designed for the IC (VIC-5′-TTAG
GACCATCAGCGAAAC-3′-NFQ-MGB). In a single reac-
tion, 0.2 μl of reverse transcriptase (40 U), 10 μl of 2×
One-Step SensiFAST Probe Lo-ROX mix (Bioline, London,
UK), 0.8 μl of each primer (20 μM), 1 μl of each probe
(10 μM), and 6.0 × 103 RNA copies/μl of IC in a final vol-
ume of 20 μl. The optimized thermal cycling profile used
was as follows: reverse transcription at 48 °C for 8 min, ini-
tial denaturation at 95 °C for 2 min, followed by 40 cycles
of 97 °C for 2 s, and 60 °C for 20s. The thermal cycling
period of the assay was short, in which viral load quantifi-
cation can be accomplished within approximately 50 min
in a single run. A synthetic DNA oligonucleotide contain-
ing the M2 gene sequence was used to generate a 10-fold
dilution series of standard concentrations, ranging from
2.0 × 101 to 2.0 × 106 RNA copies/μl. HMPV quantification
was performed in the ABI ViiA7 Real-time PCR System
(Applied Biosystems, California, USA).
The linear dynamic range of the HMPV qPCR assay
was assessed using a 6-log10 dilution series of HMPV
M2 synthetic oligonucleotide. A standard curve plotted
against quantification cycle (Cq) was built using the
serial concentration. Linear regression analysis was per-
formed to calculate the PCR efficiency and correlation
coefficient based on the standard curve. In order to as-
sess the intra- and inter-assay variability for HMPV viral
load quantification, triplicate reactions were performed
using a low (2.0 × 101 RNA copies/μl) and moderate
(2.0 × 103 RNA copies/μl) standard to determine the
mean, standard deviation (SD) and coefficient of vari-
ance (CV).
Statistical analysis
Demographic (sex, age and ethnicity) and clinical (pres-
ence of the eight common cold symptoms and estimated
number of days elapsed between symptom onset and
enrollment date) characteristics of patients infected by
different HMPV genotypes (A and B) and sub-lineages
were first assessed using the bivariate analyses (Pearson’s
chi-square for categorical variables, Independent Samples
t-test and One-way ANOVA for continuous variables),
similar to statistical techniques previously reported [12].
The overall severity of the symptoms was measured
through the summation of eight individual symptom se-
verity score (TSSS), which was modeled as a continuous
variable. Association of symptom severity with virological
factors (infection by different HMPV genotypes and
sub-lineages, and viral load in log10 RNA copies/μl) and
demographic factors was performed using bivariate ana-
lyses (Independent Samples t-Test, One-way ANOVA,
and Pearson’s bivariate correlation) and linear regression.
Lastly, comparisons of viral load between different periods
of enrollment after symptom onset (taking into account
the infection by different genotypes/sub-lineages and the
differences in demographics and symptom severity pro-
files) were made using similar analyses mentioned above.
A two-sided p value lower than 0.05 was considered statis-
tically significant. In order to control false positives in
multiple statistical tests such as One-way ANOVA and
linear regression, the Bonferroni correction was used to
lower the critical p value of significance (performed by
dividing the critical value by the number of compari-
sons corresponding to the number of levels in a group)
[26]. All analyses were performed using the Statistical
Package for Social Sciences version 22.0 (SPSS Inc.,
New York, USA).
Results
Detection and genetic diversity of HMPV
During the study period, a total of 81/3706 (2.2%)
nasopharyngeal swab specimens collected were tested
positive for HMPV. Among them, only 7/81 (8.6%) spec-
imens were cases of coinfection with other viruses
(adenovirus [n = 1], enterovirus/rhinovirus [n = 3], cor-
onavirus 229E [n = 1], influenza A (H3) + enterovirus/
rhinovirus [n = 1] and influenza B [n = 1]). Thus, as co-
infection of HMPV viruses was not common in the adult
population, we included patients with viral codetection
in subsequent analyses and was not considered as an-
other variable in this study. Phylogenetic analysis of the
F and G genes showed that 40/81 (49.4%) of detected
HMPV viruses belonged to genotype A whereas 41/81
(50.6%) belonged to genotype B (Fig. 1, Additional file 2).
Within genotype A, 25/40 (62.5%) were classified as
sub-lineage A2b, whereas 15/40 (37.5%) belonged to a
recently described sub-lineage of A2 (designated as
unique A2 sub-lineage) [15]. Within genotype B, 25/41
(61.0%) and 16/41 (39.0%) were classified as sub-lineages
B1 and B2, respectively.
Demographic and clinical association with HMPV genetic
diversity
Eighty-one outpatients (29 males and 52 females) who
were infected by HMPV had an age range of 19 to
86 years old, consisting of adults and elderly (Additional
file 2). Among them, 65 patients were grouped as young
and middle-age adults (< 65 years old), while 16 patients
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Fig. 1 Phylogenetic analysis of a) 85 fusion (F) and b) 82 attachment (G) genetic sequences. Maximum-likelihood trees were reconstructed using
PAUP version 4.0. The reliability of the branching nodes was assessed by bootstrap analysis of 1000 replicates. Bootstrap values of greater than
70% were indicated on the branch nodes. The generated sequences (dark circles) were named according to the country of isolation (Malaysia,
MY), unique sample ID and year of sample collection. Published HMPV reference strains for each genotype/sub-lineage (blue triangles) included
A1, NL00–1 (GenBank accession number: AF371337.1), A2a, CAN97–83 (AY297749.1), A2b, JPS03–240.1 (AY530095), B1, NL/1/99 (AY525843.1), and
B2, CAN98–75 (AY297748.1). Other published sequences included those from Australia (AUS), Cambodia (CAMB), Canada (CA), India (IND), Japan
(JP), Netherlands (NL), Peru (PER), Singapore (SIN), Thailand (TH), United States (USA), and Vietnam (VIET)
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were grouped as elderly (≥65 years old) (Table 1). The
majority of the patients were Malays (n = 38), followed
by Indians (n = 21), Chinese (n = 19), and other ethnic
groups (n = 3). When bivariate analyses were performed,
no significant association was observed between HMPV
genotypes (A and B) or sub-lineages (A2b, unique A2
sub-lineage, B1, and B2) with the patients’ demographics
(sex, age, and ethnicity).
The presence of common cold symptoms assessed in
this study (sneezing, nasal discharge, nasal congestion,
cough, sore throat, hoarseness of voice, muscle ache and
headache) was self-reported by the patients. The major-
ity of the patients experienced cough (n = 80/81, 98.8%)
followed by hoarseness of voice (n = 72/81, 88.9%), while
muscle ache and sneezing (n = 56/81, 69.1%) were the
least experienced by patients, respectively (Table 1). No
significant differences were noted in the manifestation of
all symptoms between different genotypes or between
different sub-lineages. Though, there were noticeably
more HMPV genotype B patients (n = 31/41, 75.6%) that
experienced nasal congestion compared to genotype A
patients (n = 23/40, 57.5%) (p = 0.084). The estimated
number of days elapsed between symptom onset and
enrollment date as reported by the patients ranged from
1 day to 2 weeks, where most patients were enrolled
after a symptomatic period of 3–5 days (n = 36/81,
44.4%) (Table 1). While no significant association was
found between different enrollment periods after symp-
tom onset and HMPV genotypes or sub-lineages, it was
observed that HMPV genotype A-infected patients
Table 1 Demographic and clinical characteristics of HMPV infection caused by different genotypes and sub-lineages
HMPV Genotype HMPV Sub-lineage
Characteristics A, n = 40 B, n = 41 p A2b, n = 25 Unique A2
sub-lineage, n = 15
B1, n = 25 B2, n = 16 p
Sex
Male, n = 29 13 16 0.540b 8 5 11 5 0.784b
Female, n = 52 27 25 17 10 14 11
Age
< 65 years old, n = 65 32 33 0.956b 20 12 22 11 0.516b
≥ 65 years old, n = 16 8 8 5 3 3 5
mean (±SD) 45.28 ± 18.26 46.15 ± 20.12 0.839a 44.36 ± 18.68 46.80 ± 18.07 44.56 ± 17.63 48.63 ± 23.91 0.892c
Ethnicity
Chinese, n = 19 12 7 0.402b 6 6 2 5 0.144b
Malay, n = 38 18 20 15 3 14 6
Indian, n = 21 8 13 3 5 9 4
Others, n = 3 2 1 1 1 0 1
Presence of Symptoms
Sneezing, n = 56 29 27 0.517b 20 9 18 9 0.346b
Nasal congestion, n = 54 23 31 0.084b 14 9 21 10 0.166b
Nasal discharge, n = 58 31 27 0.245b 20 11 16 11 0.645b
Cough, n = 80 40 40 0.320b 25 15 24 16 0.519b
Sore throat, n = 59 28 31 0.570b 19 9 21 10 0.282b
Hoarseness of voice, n = 72 36 36 0.753b 23 13 23 13 0.680b
Muscle ache, n = 56 26 30 0.426b 17 9 18 12 0.812b
Headache, n = 57 27 30 0.576b 15 12 18 12 0.541b
Estimated no. of days elapsed between symptom onset and enrollment date
≤ 1–2 days, n = 20 9 11 0.207b 5 4 7 4 0.600b
3–5 days, n = 36 15 21 11 4 12 9
≥ 6 days, n = 25 16 9 9 7 6 3
mean (±SD) 5.15 ± 3.63 4.12 ± 2.55 0.143a 4.56 ± 2.04 6.13 ± 5.28 4.20 ± 2.93 4.00 ± 1.80 0.211c
n: number of patients, SD: standard deviation
ap-value calculated by Independent Samples t-Test
bp-value calculated by Pearson’s Chi-square test
cp-value calculated by One-way ANOVA
p = level of significance (2 tailed) at the 0.05 level
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enrolled slightly later after symptom onset (5.15 ± 3.63 days)
compared to genotype B patients (4.12 ± 2.55 days)
(p = 0.143).
Symptom severity of HMPV-infected patients
A greater perceived symptom severity of HMPV-infected
patients was indicated by a higher TSSS, which was cal-
culated by the summation of eight individual symptom
severity score as reported or assessed during enrollment
[20]. Overall, the infected patients had a mean TSSS of
12.20 ± 4.58, with a range of score from 4 to 23 (max-
imum score is 24) (Additional file 2), indicating that
patients may experience a range of mild to severe re-
spiratory illnesses. When TSSS was compared between
different HMPV genotypes and sub-lineages by bivariate
and linear regression analyses, no significant differences
were observed, even though genotype B patients re-
ported higher TSSS (12.85 ± 4.67) compared to genotype
A patients (11.53 ± 4.44), with sub-lineage B1 patients
had the highest TSSS (13.56 ± 4.42) among the
sub-lineages (Table 2). Also, no significant differences of
mean TSSS were observed between different periods of
enrollment after symptom onset and no correlation with
TSSS was found when the days of enrollment after
symptom onset was treated as a continuous variable.
The mean TSSS between different sexes and between
ethnic groups was not significantly different as well, even
though male patients had a higher TSSS compared to fe-
male while the Indian ethnic group had the highest
TSSS compared to other ethnic groups (Table 2).
In terms of age, mean TSSS was significantly higher in
the young and middle-age adults who were < 65 years old
(12.86 ± 4.55) as compared to the elderly population who
were ≥ 65 years old (9.50 ± 3.71) (p = 0.008) (Table 2).
Moreover, when age was modeled as a continuous
variable, it had a significant negative correlation with TSSS
(r = − 0.335, p = 0.002). In a simple linear regression
model, for the increase of every unit (years) in age, there
was a significant decrease of 0.080 unit (score) of TSSS.
Thus, our results indicated that age was the only sig-
nificant predictor of TSSS, with the elderly patients
experiencing less severe symptoms than the young
and middle-age adults in an outpatient setting.
Though, there was no significant difference observed
in the estimated enrollment period after symptom onset
between patients who were < 65 years old (4.58 ± 3.36 days)
and ≥ 65 years old (4.81 ± 2.20 days) (p = 0.797).
The impact of viral load on symptom severity
The performance of the improved one-step RT-qPCR
assay targeting the M2 gene of HMPV was first
evaluated using a 6-log10 dilution series of HMPV M2
synthetic oligonucleotide standard. The assay produced
a typical amplification plot and a standard curve with a
correlation coefficient of 0.999 and amplification efficiency
of 96.78%, with a coefficient of determination (R2) of 0.996
(Additional file 3). The intra- and inter-assay variability
was estimated within standard range (Additional file 4).
Nasopharyngeal viral load in 78/81 HMPV-positive
specimens were quantified, with a success rate of 96.5%
(Additional file 2). Besides being able to detect all different
genotypes and sub-lineages of HMPV, the lowest quantifi-
able concentration of the assay was estimated at 13 RNA
copies/μl, while the highest viral load recorded in our spe-
cimen was 731,917 RNA copies/μl.
At different periods of enrollment after symptom onset
(≤1–2 days, 3–5 days, and ≥ 6 days), we observed that
patients who enrolled in 3–5 days had the highest viral
load (3.77 ± 1.20 log10 RNA copies/μl, n = 35) compared
to those who enrolled in ≤1–2 days (3.55 ± 1.53 log10
RNA copies/μl, n = 20) and in ≥6 days (2.93 ± 1.16 log10
RNA copies/μl, n = 23) after symptom onset (Fig. 2a,
Additional file 5). Even though no bivariate association
between viral load and periods of enrollment after symp-
tom onset was observed (p = 0.052), a post-hoc test
using the Bonferroni procedure showed that those who
enrolled in 3–5 days had higher viral load (p = 0.048,
insignificant when Bonferroni-corrected p < 0.0083
instead of p < 0.05 was used) compared to those who
enrolled in ≥6 days after symptom onset.
However, the impact of viral load on symptom severity
was investigated by performing bivariate correlation
between the estimated viral load and TSSS, in which no
significant correlation was observed (r = − 0.118, p = 0.303)
(Table 2). Taking into account the different periods of
enrollment after symptom onset, there was also no
significant correlation observed between viral load
and TSSS in these periods (Additional file 5). When
the patients’ TSSS was grouped into three categories
with scores that range from 1 to 8, 9–16, and 17–24 to re-
flect the relative symptom severity of mild, moderate, and
severe, respectively [20] (Fig. 2b), no significant differences
in viral load between the three categories of symptom
severity were observed. Though, among the group of pa-
tients with a TSSS of 1–8 (indicative of having milder
symptoms) (n = 19), those who enrolled ≥6 days after
symptom onset had a significantly lower viral load
(2.58 ± 1.07 log10 RNA copies/μl, n = 3) compared to
those who enrolled 3–5 days after symptom onset
(3.99 ± 0.81 log10 RNA copies/μl, n = 9) (p = 0.043),
but the difference was insignificant after Bonferroni
correction (Fig. 2b, Additional file 5). Overall, our
analyses showed that nasopharyngeal viral load could
not predict the severity of symptoms caused by
HMPV infection, as well as the TSSS scoring system
could not predict the amount of viral load in the pa-
tient, hence both variables were found to be not cor-
related in this study.
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Association of viral load with HMPV genetic diversity and
demographic factors
By comparing the genetic diversity of HMPV, we ob-
served that after 3–5 days of symptom onset, geno-
type A patients had a significantly higher viral load
(4.44 ± 1.07 log10 RNA copies/μl, n = 15) compared to
genotype B patients (3.27 ± 1.07 log10 RNA copies/μl,
n = 20) (p = 0.003) (Fig. 2c, Additional file 5). How-
ever, viral load differences between sub-lineages were not
significant after Bonferroni correction (p = 0.024), though
the A2b sub-lineage had a higher viral load (4.55 ± 0.96
log10 RNA copies/μl, n = 11) compared to B2 (3.07 ± 1.33
log10 RNA copies/μl, n = 8, p = 0.037) sub-lineage during
this 3–5 days period (Fig. 2d, Additional file 5). On the
other hand, we also observed that genotype A patients
who enrolled ≥6 days had a significantly lower viral load
(after Bonferroni correction) compared to those who en-
rolled 3–5 days after symptom onset (p = 0.012, post-hoc
test with Bonferroni procedure) (Fig. 2c). Lastly, no signifi-
cant viral load differences were found between the differ-
ent demographics (sex, ethnicity, and age) of patients at
any of the three periods of enrollment after symptom on-
set (Additional file 5).
Discussion
Studies assessing the risk factors such as genetic diver-
sity and viral load that contribute to the burden of ill-
ness caused by HMPV infection have generally focused
Table 2 Assessment of demographical and virological predictors for symptom severity in HMPV-infected patients
Characteristics TSSS
(mean ± SD)
p β p*
HMPV genotype
A, n = 40 11.53 ± 4.44 0.194a 1.329 0.194
B, n = 41 12.85 ± 4.67 ref.
HMPV sub-lineage
A2b, n = 25 11.16 ± 4.12 0.306b ref.
Unique A2 sub-lineage, n = 15 12.13 ± 5.03 0.973 0.515
B1, n = 25 13.56 ± 4.42 2.400 0.067
B2, n = 16 11.75 ± 4.99 0.590 0.687
Estimated no. of days elapsed between symptom onset and enrollment date r = 0.106 0.348c 0.153 0.348
≤ 1–2 days, n = 20 10.95 ± 4.77 0.373b − 1.578 0.221
3–5 days, n = 36 12.53 ± 4.35 ref.
≥ 6 days, n = 25 12.72 ± 4.75 0.192 0.872
Sex
Male, n = 29 12.41 ± 4.73 0.753a − 0.337 0.753
Female, n = 52 12.08 ± 4.54 ref.
Age r = −0.335 0.002c − 0.080 0.002
< 65 years old, n = 65 12.86 ± 4.55 0.008a ref.
≥ 65 years old, n = 16 9.50 ± 3.71 −3.362 0.008
Ethnicity
Chinese, n = 19 10.11 ± 4.31 0.054b − 2.763 0.030#
Malay, n = 38 12.87 ± 4.02 ref.
Indian, n = 21 13.33 ± 5.25 0.465 0.701
Others, n = 3 9.00 ± 4.36 − 3.868 0.151
Viral Load (log10 RNA copies/μl), n = 78 r = −0.118 0.303c − 0.206 0.584
TSSS: Total symptom severity score, n: number of patients, SD: standard deviation, ref. category with the highest number of patients is chosen as reference
aP-value calculated by Independent Samples t-Test
bP-value calculated by One-way ANOVA
cP-value calculated by bivariate correlations
p*: p-value calculated by simple linear regression
r: Pearson’s correlation coefficient
β: linear regression coefficient
statistically significant comparisons (p < 0.05) are in bold
#p-value for significance was adjusted by Bonferroni correction to p < 0.0083 (0.05/6)
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on high-risk populations such as hospitalized children
[27] or adult patients [28], immunocompromised elderly
[29], or hematopoietic cell transplant recipients [30],
with limited reports from outpatients presenting with
acute respiratory tract symptoms. While individuals
seeking and receiving outpatient care may not experi-
ence severe respiratory complications, their illnesses
contribute significantly to the overall disease burden and
transmission of the virus to susceptible individuals. The
present study investigated the severity of acute respira-
tory symptoms caused by HMPV infection in a generally
adult outpatient population, and assessed the virological
and demographical factors that may be associated with
the degree of symptom severity.
A standardized four-category scoring of the severity of
common cold symptoms has been used as a comple-
mentary measure for the impact of respiratory illness in
outpatients [16–19]. By summing up the scores of all
individual symptoms [20], we could not observe any sig-
nificant symptom severity differences (or TSSS) between
HMPV genotypes/sub-lineages in the adult outpatients
(Table 2), suggesting that the genetic diversity of HMPV
as shown in this study played limited role as a predictor
for the severity of symptoms in the outpatient settings.
Moreover, patients infected with a recently described
sub-lineage A2, which was identified based on the esti-
mated genetic distances between sub-lineages in the F
and G genes and was also found in other countries such
as China, Vietnam and Cambodia [15], did not show
more severe symptoms compared to other sub-lineages.
Several previous studies have reported the association of
HMPV genetic diversity with disease severity in children.
In one report, children infected by genotype A were
found to experience more severe acute respiratory illness
(based on a scoring method that measures the need for
hospitalization, oxygen saturation < 90% at hospital ad-
mission, and intensive care unit stay) as compared with
genotype B infection [7]. In contrast, a separate study on
young children suggested that genotype B infection may
result in greater hospitalization rate and higher clinical
score (using two scoring methods [7, 31] compared to
genotype A [6]. Yet, no significant differences in the
severity of illness or clinical manifestation have been
reported between HMPV genotypes in children in
several other studies [8, 9, 32, 33], which used other
scoring methods. The contrasting findings in these
studies highlighted that the relationship between
HMPV genetic diversity and disease severity remains
A
C
B
D
Fig. 2 Viral load at different periods of enrollment after symptom onset. a) total HMPV-infected patients, b) patients with different symptom
severity, c) patients infected with different HMPV genotypes and d) patients infected with different HMPV sub-lineages
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undetectable, probably due in part to the lack of a consen-
sus and standardized severity scoring method for outpa-
tients or hospitalized patients. Inclusion of other objective
assessment including body temperature, chest X-ray and
also respiration rate may help to improve the analysis and
reduce discordant findings between studies. In addition,
the inconclusive association between HMPV genetic diver-
sity and symptom severity could also be due to the low
number of HMPV-positive samples in this study as well as
several other studies [7, 9], which may reduce the statis-
tical power for associations [34].
It has been described in several studies that HMPV re-
infection can occur during an adult’s life due to transient
immunity or incomplete protective immune responses
for the newly evolved genotype [29, 35], indicating that
the elderly individuals are equally susceptible to reinfec-
tion. Furthermore, the possible immune dysregulation
which lead to a decreased viral clearance in the elderly
will further increase their risk of severe symptomatic in-
fection [28] and lead to higher rates of hospitalization
[36, 37]. However, unlike previous studies, we found that
elderly patients who were ≥ 65 years old had less severe
symptoms compared to young and adult patients who
were < 65 years old. As our study was conducted in the
outpatient clinic, it is possible that elderly patients with
severe respiratory symptoms may have opted to seek
immediate treatment at inpatient settings, leading to
sampling bias. Hence, such contrasting observation may
be due to the limited sampling on elderly patients who
experience more severe symptoms compared to the
young and adult patients. Similarly, even though the In-
dian ethnic group may appear to be experiencing more
severe symptoms (based on higher TSSS score) com-
pared to other ethnic groups in this study (Table 2), such
observation needs to be interpreted with caution given
the limited number of patients in our cohort. Overall, it
remains unclear if host demographic factors could be
contributing to a more severe symptom outcome in
HMPV infection.
The availability of an up-to-date RT-qPCR assay is im-
portant for sensitive, specific and rapid detection and
quantification of HMPV. Previously, assays for the de-
tection and quantification of HMPV were developed
based on limited genome sequences that belonged to the
five known genetic lineages/sub-lineages of HMPV: A1,
A2 (A2a and A2b sub-lineage), B1 and B2 [37, 38]. Be-
sides, most published assays were designed to target the
conserved regions of the nucleoprotein (N) gene [39–41]
as it is the highly transcribed and conserved gene [24, 42],
even though nucleotide mismatches between primer/
probe sets with reference sequences have been reported
[28, 41, 43, 44]. Thus, in this study, using an updated
alignment of complete reference genomes (n = 135),
primers/probes were designed to target the conserved
region of the M2 gene with a minimum coverage of 99.3%
of the global HMPV sequences (Additional file 1). The
viral load in all but three HMPV-positive specimens was
successfully captured with the lowest quantifiable concen-
tration estimated at approximately 13 RNA copies/μl,
which was more sensitive than previously published
methods [38, 43].
High nasopharyngeal HMPV viral load has been impli-
cated as an important risk factor for severe symptoms in
children who were hospitalized [12, 45] or admitted for
emergency care [46]. However, in this study, no correl-
ation was observed between viral load and symptom se-
verity in adult outpatients (Table 2, Fig. 2 and Additional
file 5). Interestingly, it was found that patients infected
with genotype A had a significantly higher peak viral
load compared to genotype B-infected patients around
3–5 days of symptom onset, suggesting that genotype A
may have a better replication fitness (or replication cap-
acity) and higher transmissibility than genotype B during
this period. However, the viral load of genotype
A-infected patients who enrolled ≥6 days were observed
to be significantly lower compared those who enrolled
3–5 days after symptom onset, due to the fact they
enrolled much later during the course of infection, in
which most viruses would have been cleared by immun-
ity. Interestingly, our findings corroborates with a previ-
ous report that demonstrated the differences in
replication fitness between HMPV genotypes in vitro
and in vivo [47]. The study by Aerts et al. showed that
HMPV genotype A replicates to a significantly higher ti-
ters than genotype B in LLC-MK2 cells and in the lungs
of BALB/c mice on day 4 post-infection, but the viral ti-
ters of genotype A decreased more rapidly than geno-
type B after day 4 [47]. As observed in other viral
genotypes/serotypes [48, 49], the differences in replica-
tion capacity may contribute to the competitive, trans-
mission and epidemiological fitness differences between
HMPV genotypes [50], which in turn may dictate the
spread and evolution of both genotypes in the human
population.
Conclusions
This study investigated the impact of HMPV genetic di-
versity and viral load (estimated using an improved
quantification assay) on symptom severity in an adult
outpatient cohort presenting with acute respiratory tract
symptoms, in which both factors were found not to be
associated with a more severe symptom outcome. Sig-
nificant difference in the viral load dynamics between
HMPV genotypes A and B was observed during the
course of infection due probably to the difference in viral
fitness, which may have important implications on virus
transmission.
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